Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Operating Margin (2023 - 2025)

Historic Operating Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 140.69%.

  • Iovance Biotherapeutics' Operating Margin rose 114200.0% to 140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.31%, marking a year-over-year increase of 3069100.0%. This contributed to the annual value of 240.92% for FY2024, which is 384940700.0% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Operating Margin stood at 140.69% for Q3 2025, which was up 114200.0% from 189.78% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Operating Margin ranged from a high of 117.48% in Q4 2024 and a low of 46254.62% during Q2 2023
  • For the 3-year period, Iovance Biotherapeutics' Operating Margin averaged around 11428.64%, with its median value being 286.7% (2024).
  • Its Operating Margin has fluctuated over the past 5 years, first soared by 459269900bps in 2024, then surged by 114200bps in 2025.
  • Iovance Biotherapeutics' Operating Margin (Quarter) stood at 25156.85% in 2023, then soared by 100bps to 117.48% in 2024, then fell by -20bps to 140.69% in 2025.
  • Its Operating Margin was 140.69% in Q3 2025, compared to 189.78% in Q2 2025 and 245.76% in Q1 2025.